Healthy adults =50 years old were immunized with either pentavalent Corynebacterium diphtheriae C7 (bêta197) cross-reactive material (CRM197) protein-conjugated pneumococcal vaccine (CV) containing 10 mug each of capsular oligosaccharides from serotypes 6B, 14,18C, 19F, and 23F or with licensed (23-valent, 25 mug/serotype) pneumococcal polysaccharide vaccine (PV).
Adverse reactions, predominantly local in nature, occurred in 20 of 23 CV recipients versus 13 of 23 PV recipients (P<. 05).
Compared with mean postvaccination antibody concentrations in PV recipients, those induced by CV were not significantly different for serotypes 6B, 14,18C, and 23F and were lower for 19F (P<. 05).
Six months later, reimmunization with PV of subjects who had initially received CV elicited a slight boost in antibody concentrations to levels that were not significantly higher than those achieved after the primary vaccination or than those in persons given a single dose of PV.
Pneumococcal vaccines containing protein-conjugated oligosaccharides may offer no advantage over currently licensed preparations containing unconjugated polysaccharides for immunization of healthy older adults.
Mots-clés Pascal : Streptococcus pneumoniae, Streptococcaceae, Micrococcales, Bactérie, Vaccination, Toxicité, Réponse immune, Efficacité, Immunoprophylaxie, Immunogénicité, Vaccin, Prévention, Adulte, Homme
Mots-clés Pascal anglais : Streptococcus pneumoniae, Streptococcaceae, Micrococcales, Bacteria, Vaccination, Toxicity, Immune response, Efficiency, Immunoprophylaxis, Immunogenicity, Vaccine, Prevention, Adult, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0201881
Code Inist : 002B05B02E. Création : 199608.